Roche Media 29. Jan. 2026 Roche’s 2025 profit blunted by weakened US dollar - Pharmaceutical Technology
Roche Media 29. Jan. 2026 Roche GLP-1 produces “robust” weight loss in late-stage obesity trial - European Pharmaceutical Review
Roche Media 29. Jan. 2026 Roche drops $100M Kiniksa fibrosis drug from phase 2 pipeline as part of quarterly clearout - Fierce Biotech
Roche Media 27. Jan. 2026 Roche Reports Positive Phase II Study Results for Dual GLP-1/GIP Receptor Agonist | PharmExec - Pharmaceutical Executive
Roche Media 27. Jan. 2026 How Roche is Scaling Production After Obesity Breakthrough - Manufacturing Digital Magazine
Roche Media 27. Jan. 2026 Roche sees GLP1/GIP drug from Carmot produce 22.5% weight loss, readies phase 3 trial - Fierce Biotech
Roche Media 27. Jan. 2026 Roche announces positive phase II results for experimental obesity drug - wkzo.com
Roche Media 27. Jan. 2026 Roche moves obesity drug to pivotal trials after mid-stage success - statnews.com
Roche Media 27. Jan. 2026 Is Roche Becoming a Contender in the Obesity Drug Market? - Healthcare Digital
Roche Media 26. Jan. 2026 Roche's Gazyva gets Health Canada approval for lupus nephritis - marketscreener.com
Roche Media 11. Jan. 2026 Roche: Making Preventative Healthcare Accessible to All - Healthcare Digital
Roche Media 9. Jan. 2026 Former Roche oncology head turns to Tubulis—Chutes & Ladders - fiercebiotech.com
Roche Media 9. Jan. 2026 Roche returns to Chinese biotech MediLink for another ADC pact - Endpoints News
Roche Media 9. Jan. 2026 Roche returns to MediLink with $570M near-term payments for ADC - Fierce Biotech
Roche Media 6. Jan. 2026 In Structure licensing deal, Roche commits $100M to shore up GLP-1 position - Fierce Biotech
Roche Media 6. Jan. 2026 Roche Clears Obesity Pill Legal Concerns With Structure Patent Agreement - BioSpace